A 65-year-old woman with atrial fibrillation on warfarin (INR 8.5) presents with acute intracerebral hemorrhage. Which agent is the drug of choice for immediate reversal of her anticoagulation?

Explanation

## Drug of Choice for Warfarin Reversal in Intracerebral Hemorrhage **Key Point:** Prothrombin complex concentrate (PCC) is the first-line agent for rapid reversal of warfarin-induced anticoagulation in acute intracerebral hemorrhage (ICH). ### Why PCC is Superior **High-Yield:** PCC provides immediate correction of INR within 10–30 minutes, whereas FFP requires large volumes and causes fluid overload; vitamin K takes 12–24 hours to work. ### Mechanism of PCC 1. **Composition:** Contains vitamin K-dependent clotting factors (II, VII, IX, X) in concentrated form 2. **Rapid INR correction:** Restores depleted coagulation factors immediately 3. **Small volume:** 10–15 mL/kg IV bolus (vs. 10–15 mL/kg FFP = 2–4 units) 4. **Minimal fluid overload:** Critical in ICH where cerebral edema worsens outcomes ### Dosing in ICH - **Standard dose:** 25 units/kg IV (typical: 1500–2500 units for adults) - **Redose:** May repeat after 12 hours if INR remains elevated - **Always combine with:** Vitamin K1 10 mg IV (slow infusion) for sustained effect ### Comparison of Reversal Agents | Agent | Onset | Duration | Volume | Cost | Indication | |-------|-------|----------|--------|------|------------| | **PCC** | 10–30 min | 12–24 hrs | Small (10–15 mL/kg) | High | **First-line for ICH** | | FFP | 30–60 min | 4–6 hrs | Large (2–4 units) | Low | Backup if PCC unavailable | | Vitamin K1 | 12–24 hrs | 7 days | Minimal | Low | Adjunct (not monotherapy) | | Idarucizumab | 10 min | 24 hrs | Small | Very high | Dabigatran reversal only | **Clinical Pearl:** In ICH, every minute counts. PCC's rapid onset prevents hematoma expansion, whereas FFP's slow onset and large volume may worsen cerebral edema and increase mortality. ### Management Algorithm for Warfarin-Associated ICH ```mermaid flowchart TD A[Warfarin-associated ICH]:::outcome --> B{INR elevated?}:::decision B -->|Yes| C[Measure INR, PT, aPTT]:::action C --> D[Administer PCC 25 units/kg IV]:::action D --> E[Add Vitamin K1 10 mg IV]:::action E --> F[Recheck INR at 30 min]:::outcome F --> G{INR normalized?}:::decision G -->|Yes| H[Continue supportive care]:::action G -->|No| I[Consider repeat PCC dose]:::action B -->|No| J[No reversal needed]:::action ``` ### Why Other Options Are Incorrect **FFP (Fresh Frozen Plasma):** - Slower onset (30–60 min vs. 10–30 min) - Requires large volumes (2–4 units = 800–1200 mL) - Increases intracranial pressure and worsens outcomes in ICH - Now considered **second-line** if PCC unavailable **Vitamin K1 (Phytonadione):** - Onset too slow (12–24 hours) - Inadequate for acute ICH where rapid reversal is critical - Must be combined with PCC or FFP for immediate effect - Useful for sustained reversal after acute phase **Idarucizumab:** - Specific reversal agent for **dabigatran only** (direct thrombin inhibitor) - Has no role in warfarin reversal - Not indicated in this case ### Evidence & Guidelines **High-Yield:** American Heart Association (AHA) 2019 Stroke Guidelines recommend PCC as Class IIa evidence for warfarin-associated ICH, with FFP as backup if PCC unavailable. [cite:Harrison 21e Ch 296; American Heart Association Stroke Guidelines 2019]